In particular, there are studies that did not report a specific profile of autoantibodies, including anti-IFN and anti-IFN-α2 autoantibodies or antinuclear (ANA) antibodies [196,246], that could differentiate patients with LC from recovered patients or controls [174,193,196,246]. This evidence concerns the gene IFNA2 and laryngotracheoesophageal cleft.